The field of cell and gene therapy (CGT) has made remarkable strides in recent years, offering new hope to patients across an increasingly wide range of conditions. However, the field’s growth has ...
Dublin, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The "Viral Vector Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive ...
Oxford, UK – 11 March 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or the “Company"), a leading gene and cell therapy group, is pleased to announce that it has completed its deal with ...
Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...
From rare diseases to common chronic conditions, advances in viral vector-based gene therapies are bringing exciting new clinical possibilities to the table. But current costs per dose land as high as ...
Thermo Fisher is cutting the headcount at two of its US facilities by 300 as the company continues to overhaul its viral vector manufacturing output. Announcement of the layoffs was disclosed via a ...
COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology (Matica Bio), a leading contract development and manufacturing organization (CDMO) for viral vectors, announced today the successful ...
LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell” or the “Company”), a specialist viral vector Contract Development and Manufacturing Organisation (“CDMO”) for cell and gene therapy ...
Viral vector manufacturing continues to face challenges in delivering consistent quality and achieving high productivity at scale. This webinar will highlight how CDMO innovation drives improvements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results